SEC EDGAROct 14$HTFL

Farquhar John C.M. sold $1.9M of HTFL

Farquhar John C.M. (Chief Executive Officer) sold 38,900 shares of Heartflow, Inc. (HTFL) at $49.57 ($1.93M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Farquhar John C.M.

Published Oct 14, 2026, 10:05 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 14, 2026, 10:06 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$HTFL

Bearish

medium confidence

Mentioned

$HTFL

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$HTFLBearishLow

Why it matters

The filing provides fresh, material information about insider holdings, which can influence short‑term sentiment.

Market read

First‑report insider sale by the CEO, modest size, may cause slight negative bias in HTFL trading.

What to watch

Potential upcoming clinical data or partnership news could offset the sell‑off pressure.

Relevance 5/10Novelty 6/10Timing: post‑market 2026‑10‑14

Background

SEC Form 4 filing discloses an insider transaction by Heartflow's CEO.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HTFLBearishMedium confidence

Context

CEO Farquhar sold 38,900 shares at $49.568 each, total $1.93M, reducing his stake to 283,014 shares.

Expected impact

likely pressure as the market prices in the insider sell.

Evidence & confidence

A $1.9M open‑market sale by the chief executive is material but not large enough to trigger a sharp move; traders may watch for further insider activity.

Market effects

Sector

Minimal impact on the broader medical‑device sector; the sale is company‑specific.

Regional

U.S. market only; no regional ripple effect.

Global

Low; limited to investors tracking HTFL.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals; price may remain stable.

Key entities

company
Heartflow, Inc.
Medical‑device firm listed on NASDAQ (HTFL).
person
Farquhar John C.M.
Chief Executive Officer of Heartflow.

Read at source ← All news

Med

HeartFlow: 3 Key Takeaways for Long-Term Investors

HeartFlow reported revenue growth outpacing expenses, narrowing operating losses. The company has $253M in cash and expects to achieve positive cash flow by mid-2028. It aims for an 85% non-GAAP gross margin and is expanding its platform with new products like PCI Navigator. Management highlights structural advantages and growing clinical evidence.

finance.yahoo.comNov 14

Med

Canaccord Genuity maintains HeartFlow at Buy, raises price target to $69 from $56

Canaccord Genuity raised its price target for HeartFlow to $69 from $56, maintaining a Buy rating. The new target suggests a 15.2% upside from the Nov 12 close of $59.92. Recent analyst price targets for HeartFlow range from $64 to $70.

tradingview.comNov 13

High

Stifel maintains HeartFlow at Buy, raises price target to $70 from $45

Stifel upgraded its price target for HeartFlow to $70 from $45, a 55.6% increase, implying 16.8% upside from the Nov 12 close of $59.92. The firm maintained its Buy rating on the company.

tradingview.comNov 13

$HTFLMed

Stifel raises HeartFlow stock price target to $70 on strong growth

Stifel raised its price target on HeartFlow (NASDAQ:HTFL) to $70 from $45, citing strong Q3 2026 results. Revenue was $72.9M, beating estimates and showing 57% YoY growth. The company raised its full-year revenue guidance to $262M-$264M. Shares are near a 52-week high, up 106% YTD, but some analysts consider the stock overvalued.

investing.comNov 13

$HTFLHighAI 8/10

HeartFlow (HTFL) Q3 2026 Earnings Call Transcript

HeartFlow (HTFL) reported Q3 2026 revenue of $72.9M, up 57% YoY, driven by Plaque adoption and FFRCT utilization. They raised full-year revenue guidance to $262M-$264M, up 49%-50% YoY. Non-GAAP gross margin guidance was increased to 82.5%, with midterm profitability goals reaffirmed. Commercial adoption and clinical evidence support growth.

finance.yahoo.comNov 13

$HTFLMedAI 8/10

What Heartflow (HTFL) Said on Its Q3 Earnings Call

Heartflow (HTFL) expects to reach cash flow profitability by mid-2028, with declining operating expenses and narrowing losses. The company anticipates 1,300 Plaque Analysis-activated accounts by year-end and 37% year-over-year FFRct volume growth in Q4. Plaque Analysis pricing is expected to be flat sequentially, with a 10% increase in Q1 2027. Clinical data shows Plaque Analysis reduces major cardiovascular events and heart attack rates.